TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED

Second Quarter Financial Statement (*) And Dividend Announcement

1(a) Condensed Consolidated Interim Statement of Profit or Loss and Other Comprehensive Income

		The Group					
	Note	**3-month period from 1 April to 30 June 2026 RMB'000**	3-month period from 1 April to 30 June 2025 RMB'000	Change %	**6-month period from 1 January to 30 June 2026 RMB'000**	6-month period from 1 January to 30 June 2025 RMB'000	Change %
Revenue	2	**939,387**	1,195,219	(21)	**2,454,591**	2,650,519	(7)
Cost of sales	2	**(267,306)**	(312,065)	(14)	**(627,782)**	(714,834)	(12)
Gross profit		**672,081**	883,154	(24)	**1,826,809**	1,935,685	(6)
Interest income		**2,113**	1,393	52	**5,426**	4,740	14
Dividend income		**92**	92	-	**92**	92	-
Other income and gains		**14,689**	1,586,587	(99)	**34,997**	1,603,391	(98)
Marketing and distribution costs		**(265,128)**	(476,601)	(44)	**(798,630)**	(1,020,543)	(22)
Research and development costs		**(50,148)**	(35,774)	40	**(79,953)**	(61,552)	30
Administrative expenses		**(108,988)**	(101,276)	8	**(203,839)**	(190,619)	7
Finance costs		**(128)**	(168)	(24)	**(313)**	(418)	(25)
Other losses		**(12,007)**	(4,467)	n.m	**(50,664)**	(20,963)	n.m
Share of profit of associates		**5,471**	(22,606)	n.m	**18,419**	17,211	7
Profit before income tax		**258,048**	1,830,334	(86)	**752,344**	2,267,024	(67)
Income tax expense	3	**(37,546)**	(279,030)	(87)	**(108,772)**	(343,933)	(68)
Profit, net of tax		**220,502**	1,551,304	(86)	**643,572**	1,923,091	(67)

		The Group					
	Note	**3-month period from 1 April to 30 June 2026 RMB'000**	3-month period from 1 April to 30 June 2025 RMB'000	Change %	**6-month period from 1 January to 30 June 2026 RMB'000**	6-month period from 1 January to 30 June 2025 RMB'000	Change %
Other Comprehensive Loss Items that will not be reclassified to profit or loss:							
Change in fair Value of equity investment at FVTOCI, net of tax		**-**	(43)	n.m	**-**	(78)	n.m
Share of other comprehensive (loss)/ income from equity-accounted associates, net of tax		**(465)**	-	n.m	**839**	(79)	n.m
Other Comprehensive Income Items that may be reclassified subsequently to profit or loss:							
Other reserve reclassified to profit or loss upon disposal of equity interests in an associate, net of tax		**-**	(600)	n.m	**(2,234)**	(600)	n.m
Total Other Comprehensive (loss)/ income, Net of Tax		**(465)**	(643)	(28)	**(1,395)**	(757)	84
Total comprehensive income		**220,037**	1,550,661	(86)	**642,177**	1,922,334	(67)

		The Group					
	Note	**3-month period from 1 April to 30 June 2026 RMB'000**	3-month period from 1 April to 30 June 2025 RMB'000	Change %	**6-month period from 1 January to 30 June 2026 RMB'000**	6-month period from 1 January to 30 June 2025 RMB'000	Change %
Profit, net of tax attributable to:							
Owners of the parent		**220,946**	1,553,375	(86)	**644,751**	1,927,623	(67)
Non-controlling interests		**(444)**	(2,071)	(79)	**(1,179)**	(4,533)	(74)
		220,502	1,551,304	(86)	**643,572**	1,923,090	(67)
Total comprehensive income attributable to:							
Owners of the parent		**220,481**	1,552,732	(86)	**643,356**	1,926,866	(67)
Non-controlling interests		**(444)**	(2,071)	(79)	**(1,179)**	(4,533)	(74)
		220,037	1,550,661	(86)	**642,177**	1,922,333	(67)
Earnings per ordinary share for the period based on net profits after deducting any provision for preference dividends:							
Based on weighted average number of ordinary share on issue		**0.29**	2.01	(86)	**0.84**	2.50	(66)

(*) prepared under International Financial Reporting Standards

n.m Not Meaningful

Additional information on the Condensed Consolidated Interim Statement of Profit or Loss and Other Comprehensive Income. The following significant items of gains / (charges) were included in the statement of income.

	The Group					
	3-month period from 1 April to 30 June 2026 RMB'000	3-month period from 1 April to 30 June 2025 RMB'000	Change %	**6-month period from 1 January to 30 June 2026 RMB'000**	6-month period from 1 January to 30 June 2025 RMB'000	Change %
Profit, net of tax is arrived at after crediting / (charging):						
Other income (including government grant)	**15,444**	26,164	(41)	**32,699**	42,968	(24)
Interest income	**2,113**	1,393	52	**5,426**	4,740	14
Interest on borrowings	**(128)**	(168)	(24)	**(313)**	(418)	(25)
Allowance for impairment on trade receivables – reversal / (loss)	**(4,437)**	(4,017)	10	**(6,945)**	(9,476)	(27)
Allowance for impairment on other receivables – reversal / (loss)	**(101)**	(482)	(79)	**72**	(526)	n.m
Impairment loss on inventories	**(6,078)**	297	n.m	**(42,156)**	(8,507)	n.m
Foreign currency translation losses, net	**(559)**	62	n.m	**(500)**	41	n.m
Gain on disposal of property, plant and equipment, intangible assets and other non-current assets	**(776)**	167	n.m	**(181)**	75	n.m
Dividend income	**92**	92	-	**92**	92	-
Proceeds from disposal of a subsidiary	**-**	17,377	n.m	**-**	17,377	n.m
Proceeds from disposal of an associate	**-**	1,542,929	n.m	**2,226**	1,542,929	(100)

Depreciation and amortisation	**(30,512)**	(30,404)	0	**(60,912)**	(59,152)	3

1(b)(i) Condensed Interim Statements of Financial Position

		The Group			The Company		
	Note	**As at 30 June 2026 RMB'000**	As at 31 December 2025 RMB'000	Change %	**As at 30 June 2026 RMB'000**	As at 31 December 2025 RMB'000	Change %
ASSETS							
Non-current assets							
Property, plant and equipment		**1,109,042**	1,133,999	(2)	**896,511**	914,299	(2)
Right-of-use assets		**9,957**	7,548	32	**2,533**	1,861	36
Investment properties		**108,844**	110,367	(1)	**108,844**	110,367	(1)
Land use rights		**221,020**	224,507	(2)	**188,801**	191,776	(2)
Intangibles assets		**82,190**	86,639	(5)	**75,561**	78,966	(4)
Goodwill	12						
Investment in subsidiaries	7	-	-		**933,404**	933,404	-
Investment in associates	8	**1,177,469**	1,165,662	1	**1,177,469**	1,165,662	1
Other financial assets	9	**1,192,442**	1,427,139	(16)	**1,059,868**	1,273,018	(17)
Deferred tax assets		**355,484**	341,007	4	**329,599**	315,253	5
Other assets	10	**48,103**	38,347	25	**37,208**	30,762	21
Total non-current assets		**4,304,551**	4,535,215	(5)	**4,809,798**	5,015,368	(4)
Current assets							
Inventories		**1,111,255**	1,132,968	(2)	**1,001,384**	1,026,147	(2)
Trade and other receivables	11	**1,492,046**	1,603,694	(7)	**1,351,428**	1,456,156	(7)
Other financial assets	9	**1,084,962**	3,316,008	(67)	**921,413**	3,191,129	(71)
Other assets	10	**92,728**	85,422	9	**71,457**	66,133	8
Cash and cash equivalents		**2,447,803**	1,016,427	n.m	**2,158,859**	765,339	n.m
Total current assets		**6,228,794**	7,154,519	(13)	**5,504,541**	6,504,904	(15)
Total assets		**10,533,345**	11,689,734	(10)	**10,314,339**	11,520,272	(10)

		The Group			The Company		
		As at 30 June 2026 RMB’000	As at 31 December 2025 RMB’000	Change %	**As at 30 June 2026 RMB’000**	As at 31 December 2025 RMB’000	Change %
EQUITY							
Equity							
Share capital	13	**770,094**	770,094	**-**	770,094	**770,094**	**-**
Share premium		**1,206,930**	1,206,930	**-**	1,206,930	**1,206,930**	**-**
Retained earnings		**3,845,074**	5,002,346	**(23)**	3,485,352	**4,681,566**	**(26)**
Other reserves		**118,734**	120,129	**(1)**	533,383	**534,778**	**(0)**
Total equity attributable to equity holders of the Company		**5,940,832**	7,099,499	**(16)**	5,995,759	**7,193,368**	**(17)**
Non-controlling interests		**(733)**	446	**n.m**			
Total equity		**5,940,099**	7,099,945	**(16)**	5,995,759	**7,193,368**	**(17)**
LIABILITIES							
Non-current liabilities							
Deferred tax liabilities		**210**	276	(24)	**-**	-	
Trade payables		**2,399**	2,399	-	**2,259**	2,259	-
Lease liabilities		**5,144**	4,658	10	**842**	510	65
Other liabilities		**75,017**	76,018	(1)	**62,183**	63,067	(1)
Total non-current liabilities		**82,770**	83,351	(1)	**65,284**	65,836	(1)
Current liabilities							
Income tax payable		**49,174**	29,216	68	**47,303**	25,192	88
Trade and other payables	15	**4,164,104**	4,212,730	(1)	**3,931,196**	3,991,547	(2)
Other financial liabilities	14	**79,393**	57,903	37	**74,393**	48,864	52
Lease liabilities		**4,349**	3,125	39	**1,384**	1,190	16
Other liabilities		**213,456**	203,464	5	**199,020**	194,275	2
Total current liabilities		**4,510,476**	4,506,438	0	**4,253,296**	4,261,068	(0)
Total liabilities		**4,593,246**	4,589,789	0	**4,318,580**	4,326,904	(0)
Total equity and liabilities		**10,533,345**	11,689,734	(10)	**10,314,339**	11,520,272	(10)

1(b)(ii) Condensed Interim Statements of Changes in Equity

All in RMB'000

Group	Share capital	Share premium	Other reserves	Retained earnings	Parent sub-total	Non-controlling interests	Total equity
Balance at 1 January 2026	770,094	1,206,930	120,129	5,002,346	7,099,499	446	7,099,945
Total comprehensive income for the period	-	-	(1,395)	644,749	643,354	(1,179)	642,175
Dividends	-	-	-	(1,802,021)	(1,802,021)	-	(1,802,021)
Balance at 30 June 2026	770,094	1,206,930	118,734	3,845,074	5,940,832	(733)	5,940,099

Group	Share capital	Share premium	Other reserves	Retained earnings	Parent sub-total	Non-controlling interests	Total equity
Balance at 1 January 2025	770,094	1,206,930	122,794	5,743,776	7,843,594	6,344	7,849,938
Total comprehensive income for the period	-	-	(757)	1,927,623	1,926,866	(4,533)	1,922,333
Dividends	-	-	-	(985,721)	(985,721)	-	(985,721)
Liquidation of a subsidiary	-	-	194	-	194	14,376	14,570
Balance at 30 June 2025	770,094	1,206,930	122,231	6,685,678	8,784,933	16,187	8,801,120

All in RMB'000

Company	Share capital	Share premium	Other reserves	Retained earnings	Total equity
Balance at 1 January 2026	770,094	1,206,930	534,778	4,681,566	7,193,368
Total comprehensive income for the period	-	-	(1,395)	605,807	604,412
Dividends	-	-	-	(1,802,021)	(1,802,021)
Balance at 30 June 2026	770,094	1,206,930	533,383	3,485,352	5,995,759

Company	Share capital	Share premium	Other reserves	Retained earnings	Total equity
Balance at 1 January 2025	770,094	1,206,930	537,637	5,531,353	8,046,014
Total comprehensive income for the period	-	-	(757)	1,868,354	1,867,597
Dividends	-	-	-	(985,721)	(985,721)
Balance at 30 June 2025	770,094	1,206,930	536,880	6,413,986	8,927,890

1(c) Condensed Interim Consolidated Statement of Cash Flows

	The Group			
	3-month period from 1 April to 30 June 2026 RMB'000	3-month period from 1 April to 30 June 2025 RMB'000	**6-month period from 1 January to 30 June 2026 RMB'000**	6-month period from 1 January to 30 June 2025 RMB'000
Cash flows from operating activities				
Profit before income tax	**258,048**	1,830,334	**752,344**	2,267,024
Interest income	**(2,113)**	(1,393)	**(5,426)**	(4,740)
Interest expense	**128**	168	**313**	418
Dividend income	**(92)**	(92)	**(92)**	(92)
Gain upon maturity and disposal of financial assets	**(13,288)**	(16,477)	**(28,536)**	(30,135)
Share of profit of equity-accounted associates	**(5,471)**	22,606	**(18,419)**	(17,211)
Depreciation and amortisation of property, plant and equipment, investment properties, land use rights and intangible assets	**30,512**	30,404	**60,912**	59,152
Gain on disposals of property, plant and equipment, intangible assets and other non-current assets	**776**	(167)	**181**	(75)
Impairment on trade and other receivables – loss	**10,616**	4,201	**49,029**	18,509
Proceeds from disposal of a subsidiary	-	(17,377)	-	(17,377)

	The Group			
	3-month period from 1 April to 30 June 2026 RMB'000	3-month period from 1 April to 30 June 2025 RMB'000	**6-month period from 1 January to 30 June 2026 RMB'000**	6-month period from 1 January to 30 June 2025 RMB'000
Proceeds from disposal of an associate	**-**	(1,542,929)	**(2,226)**	(1,542,929)
Operating cash flows before changes in working capital	**279,116**	**309,278**	**808,080**	732,544
Inventories	**(38,086)**	(7,756)	**(11,985)**	68,233
Trade and other receivables	**346,317**	(98,786)	**126,358**	(478,078)
Other non-financial assets	**(24,290)**	4,244	**(23,615)**	12,261
Trade and other payables	**(147,839)**	(2,675)	**23,176**	315,640
Cash restricted in use	-	-	**(230)**	-
Other non-financial liabilities	**68,918**	(11,259)	**8,991**	(63,046)
Net cash flows from operations	**484,136**	193,046	**930,775**	587,554
Income tax paid	**(76,328)**	(62,223)	**(104,111)**	(360,942)
Net cash generated from operating activities	**407,808**	130,823	**826,664**	226,612
Cash flows from investing activities				
Purchase of property, plant and equipment, intangibles, land use rights and investment properties	**(19,013)**	(17,811)	**(35,417)**	(41,816)
Acquisition of financial assets	**(1,310,000)**	(530,000)	**(2,035,000)**	(2,670,000)
Capital contribution into an associate	**-**	(31,706)	**-**	(31,706)
Proceeds from disposal of financial assets	**2,400,000**	2,613,467	**4,472,590**	3,183,467
Dividends income received from associates and financial assets	**3,092**	92	**3,092**	92
Proceeds from disposals of property, plant and equipment, intangible assets and other assets	**134**	7	**134**	64
Interest income received	**64,933**	8,383	**79,704**	16,902
Net cash generated from/ (used in) investing activities	**1,139,146**	2,042,432	**2,485,103**	457,003

	The Group			
	3-month period from 1 April to 30 June 2026 RMB'000	3-month period from 1 April to 30 June 2025 RMB'000	**6-month period from 1 January to 30 June 2026 RMB'000**	6-month period from 1 January to 30 June 2025 RMB'000
Cash flows from financing activities				
Dividends paid	**(100)**	-	**(1,877,209)**	-
Interest expense paid	**(40)**	(16)	**(78)**	(32)
Repayment of lease liabilities	**(779)**	(753)	**(2,641)**	(960)
Net cash generated from/ (used in) financing activities	**(919)**	(769)	**(1,879,928)**	(992)
Net increase in cash and cash equivalents	**1,546,035**	2,172,486	**1,431,839**	682,623
Unrealised foreign exchange adjustments	**(355)**	3	**(693)**	1
Cash and cash equivalents, consolidated statement of cash flows, beginning balance	**901,893**	1,454,568	**1,016,427**	2,944,433
Cash and cash equivalents, consolidated statement of cash flows, ending balance	**2,447,573**	3,627,057	**2,447,573**	3,627,057

Notes to the Condensed Interim Financial Statements

30 June 2026

1. General

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the "**Company**") is incorporated in the People's Republic of China (the "**PRC**") as a joint stock limited company. The Company is listed on the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") and the Shanghai Stock Exchange (the "**SSE**").

The financial statements are presented in Chinese Renminbi ("**RMB**") and have been rounded to the nearest thousand ("**RMB'000**") unless when otherwise indicated, and they cover the Company and its subsidiaries (collectively, the "**Group**"), and the Group's interests in associates.

The board of directors of the Company had, on 13 August 2026, approved and authorised these condensed interim financial statements for announcement on SGXNET.

The principal activities of the Group are disclosed in Note 2 on segment information.

The registered office of the Company is located at 17 Baidi Road, Nankai District, Tianjin, the PRC 300193. The principal place of business of the Company is in Tianjin, the PRC.

The financial information contained in this announcement has neither been audited nor reviewed by the auditors.

The latest audited annual financial statements were not subject to an adverse opinion, qualified opinion or disclaimer of opinion.

The Company is not required to announce its quarterly financial statements on SGXNET pursuant to the requirements of the listing manual of the SGX-ST (the "**Listing Manual**"). However, since the Company is required to announce its quarterly financial statements in accordance with the requirements of the SSE, the Company is voluntarily announcing its quarterly financial statements on SGXNET.

These condensed consolidated interim financial statements have been prepared in accordance with the International Financial Reporting Standards issued by the International Accounting Standards Board and the provisions of the SGX Mainboard Listing Rules.

The accounting policies and methods of computation applied in these condensed consolidated interim financial statements are consistent with those of the latest audited annual financial statements. However, the typical notes and information included in the latest audited annual financial statements are not included in these interim financial statements except for the selected explanatory notes included to explain events and transactions that are significant to an understanding of the changes in the performance and financial position of the Group since the latest audited annual financial statements.

The estimates and assumptions contained in these condensed consolidated interim financial statements are periodically monitored to ensure that they incorporate all relevant information available at the date when the financial statements are prepared. However, this does not prevent actual figures differing from estimates. The nature and the carrying amount of such significant assets and liabilities are disclosed with further details in the relevant Notes to these condensed consolidated interim financial statements.

2. Financial information by operating segments

2A. Information about reportable segment profit or loss

For management purposes the Group is segregated into the Chinese Medicine, Western Medicine and Raw Chinese Medicine & Pieces major strategic operating segments.

2B. Profit or loss from continuing operations and reconciliations

	Chinese medicine	Western medicine	Raw Chinese Medicine & Pieces	Others	Total
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
6-month period ended 30 June 2026					
Revenue	**2,248,966**	**26,784**	**129,451**	**49,390**	**2,454,591**
Cost of sales	**(510,236)**	**(14,281)**	**(73,932)**	**(29,333)**	**(627,782)**
Gross profit	**1,738,730**	**12,503**	**55,519**	**20,057**	**1,826,809**
6-month period ended 30 June 2025					
Revenue	2,410,163	46,833	154,486	39,037	2,650,519
Cost of sales	(573,390)	(26,572)	(95,710)	(19,162)	(714,834)
Gross profit	1,836,773	20,261	58,776	19,875	1,935,685

2C. Disaggregation of revenue from contracts with customers

	Group	
	6-month period ended 30 June 2026 RMB'000	6-month period ended 30 June 2025 RMB'000
Sale of goods recognised at point in time	**2,448,948**	2,649,267
Revenue recognised over time	**5,643**	1,252
	2,454,591	2,650,519

3. Income tax

Components of tax expense recognised in profit or loss

	Group	
	6-month period ended 30 June 2026 RMB'000	6-month period ended 30 June 2025 RMB'000
Current income tax		
Current income tax	**123,317**	367,536
Adjustments in respect of prior years		
	123,317	367,536
Deferred tax		
Deferred tax	**(14,545)**	(23,603)
	108,772	343,933

	Group	
	6-month period ended 30 June 2026 RMB'000	6-month period ended 30 June 2025 RMB'000
Profit before tax	**752,344**	2,267,024
Loss: Share of profit of equity-accounted associates	**(18,419)**	(17,211)
	733,925	2,249,813
Income tax expense at the above rate	**183,481**	562,453
Effect of concessionary tax rate at 15%	**(73,347)**	(224,520)
Non-deductible items	**1,838**	4,479
Non-taxable items	**-**	-
Tax incentive	**(10,145)**	(5,124)
Unrecognised deferred tax assets	**6,945**	6,645
	108,772	343,933

4. Disposal of subsidiaries/ associated companies

There was no disposal of subsidiaries for the current financial period reported on.

In particular, for the purposes of Rule 706A of the Listing Manual, for the current financial period reported on, the Group had not disposed of shares resulting in a company ceasing to be a subsidiary or an associated company of the Company and had also not disposed of shares resulting in the Company reducing its shareholding percentage in a subsidiary or an associated company.

For completeness, Tianjin Bio-Chip Co. (天津生物芯片技术有限责任公司) ("**Bio-Chip Co.**"), an associated company in which the Company held a 26.4% equity interest, was placed into liquidation during the current financial period reported on and the liquidation was completed before 30 June 2026. Bio-Chip Co. has therefore ceased to be an associated company of the Company.

5. Dividends on equity shares

	6-month period ended 30 June 2026		6-month period ended 30 June 2025	
	Final dividend (FY2025)	**Interim dividend (FY2025)**	Final dividend (FY2024)	Interim dividend (FY2024)
Type	**Cash**	**Cash**	Cash	-
Dividend rate	**RMB2.34 per ordinary share**	**RMB2.45 per ordinary share**	RMB1.28 per ordinary share	-
Record date	**30 June 2026**	**2 February 2026**	26 June 2025	-
Date paid or payable	**10 July 2026**	**12 February 2026**	4 July 2025	-

The total dividends paid on ordinary shares for the financial year ended 31 December 2025 ("**FY2025**") were RMB 3,688,751,965.24, comprising the interim dividend of RMB 1,886,731,172.2 and the final dividend of RMB 1,802,020,793.04 (FY2024: RMB 985,802,593.28).

6. Acquisition of subsidiaries/subsidiary/business combination

There was no company which became a subsidiary of the Company through acquisition or business combination for the current financial period reported on.

In particular, for the purposes of Rule 706A of the Listing Manual, for the current financial period reported on, the Group had not acquired any shares of a company resulting in such company becoming a subsidiary or an associated company of the Company and had also not acquired any shares resulting in the Company increasing its shareholding percentage in a subsidiary or an associated company.

7. Investments in subsidiaries

	Company	
	As at 30 June 2026 RMB'000	As at 31 December 2025 RMB'000
Movements during the period:		
At beginning of the period	**933,404**	1,048,534
Additions	**-**	3,000
Reductions	**-**	(118,130)
At the end of the period	**933,404**	933,404

8. Investments in associates

	Group	
	As at 30 June 2026 RMB'000	As at 31 December 2025 RMB'000
Movements in carrying value:		
At beginning of the period	**1,165,662**	1,293,528
Share of profit of associates	**31,563**	(21,966)
Dividends	**(3,000)**	(14,400)
Additions	**-**	-
Disposals	**(17,595)**	(80,537)
Other equity movements	**839**	(10,963)
At end of the period	**1,177,469**	1,165,662

9. Other financial assets

	Group	
	As at 30 June 2026 RMB'000	As at 31 December 2025 RMB'000
Other financial assets - current assets		
Investment in debt instruments at amortised cost	**1,084,962**	3,316,008
Other financial assets - non-current assets		
Investment in debt instruments at amortised cost	**1,192,442**	1,427,139
Investment in equity instruments at fair value through other comprehensive income	**-**	-
	1,192,442	1,427,139
	2,277,404	4,743,147

10. Other non-financial assets

	Group	
	As at 30 June 2026 RMB'000	As at 31 December 2025 RMB'000
Current assets		
Prepayments	**40,702**	32,912
Right of return assets	**5,844**	6,542
Value-added taxes recoverable	**44,552**	45,116
Income tax recoverable	**1,630**	852
	92,728	85,422
Non-current assets		
Prepayment	**48,103**	38,347
	140,831	123,769

11. Trade and other receivables

	Group	
	As at 30 June 2026 RMB'000	As at 31 December 2025 RMB'000
Trade receivables		
Bills receivable	**683,878**	598,111
Outside parties	**587,532**	704,044
Associates	**92,695**	151,749
Related parties	**209,240**	223,877
Less: Allowance for credit impaired	**(16,330)**	(17,666)
Less: Allowance for expected credit losses	**(97,080)**	(88,800)
	1,459,935	1,571,315
Other receivables		
Dividends receivable	**3,016**	3,016
Outside parties	**46,638**	47,545
Associates	**17,522**	17,522
Related parties	**3,807**	3,215
Less: Allowance for expected credit losses	**(38,872)**	(38,919)
	32,111	32,379
Total	**1,492,046**	1,603,694

The ageing of the trade receivables balances was as follows:

	Group		
	Gross amount RMB'000	ECL %	Loss allowance RMB'000
As at 30 June 2026			
Within 1 year	**734,617**	**0.13**	**952**
1 – 2 years	**40,373**	**20**	**8,075**
2 – 3 years	**20,187**	**50**	**10,093**
Over 3 years	**77,960**	**100**	**77,960**
Total	**873,137**		**97,080**
As at 31 December 2025			
Within 1 year	946,369	0.13	1,227
1 – 2 years	30,853	20	6,171
2 – 3 years	6,761	50	3,381
Over 3 years	78,021	100	78,021
Total	1,062,004		88,800

12. Goodwill

	Group	
	As at 30 June 2026 RMB'000	As at 31 December 2025 RMB'000
Beginning balance	**-**	12,301
Additions	**-**	-
Reductions	**-**	(12,301)
Ending balance	**-**	-

13. Share capital and treasury shares

	Group			
	Number of ordinary shares		Amount of share capital	
	As at 30 June 2026 '000	As at 31 December 2025 '000	**As at 30 June 2026 RMB'000**	As at 31 December 2025 RMB'000
Movements in share capital:				
At beginning of the period	**770,094**	770,094	**770,094**	770,094
Restricted A-Shares buy-back	**-**	-	**-**	-
At end of the period	**770,094**	770,094	**770,094**	770,094

There has been no change in the Company's share capital since the end of the previous period reported on, being 31 March 2026.

The Company does not have any shares that may be issued on conversion of any outstanding convertibles as at 30 June 2026 and 30 June 2025.

The Company does not hold any treasury shares and there are no subsidiary holdings as at 30 June 2026 and 30 June 2025.

	As at 30 June 2026	As at 31 December 2025
Number of issued shares excluding treasury shares	**770,094,356**	770,094,356
Number of treasury shares held	**Nil**	Nil

14. Aggregate amount of the group's borrowings and debt securities

	Secured		Unsecured	
	As at 30 June 2026 RMB'000	As at 31 December 2025 RMB'000	**As at 30 June 2026 RMB'000**	As at 31 December 2025 RMB'000
Repayable in one year or less, or on demand:				
Bank borrowings	**5,000**	5,000	**74,393**	52,903
Subtotal	**5,000**	5,000	**74,393**	52,903
Repayable after one year:				
Bank borrowings	**-**	-	**-**	-
Subtotal	**-**	-	**-**	-
Total	**5,000**	5,000	**74,393**	52,903

14A. Details of any collaterals

The secured bank borrowings disclosed above, with an aggregate principal amount of RMB 5 million, are secured by two properties owned by NewScen Coast Bio-Pharmaceutical Co., Ltd. (天津中新科炬生物制药股份有限公司), a subsidiary of the Company, with such properties valued at approximately RMB 11,419,584.80 in aggregate as at 30 June 2026.

15. Trade and other payables

	Group	
	As at 30 June 2026 RMB'000	As at 31 December 2025 RMB'000
Trade payables		
Bills payable	**-**	-
Outside parties	**227,244**	213,930
Associates	**4,678**	3,332
Related parties	**380**	792
Employee benefits payables	**263,591**	225,051
	495,893	443,105
Other payables		
Outside parties	**1,754,988**	1,753,631
taxes payables	**59,483**	86,719
Dividend payable	**1,843,558**	1,919,093
Associates	**-**	-
Related parties	**10,182**	10,182
Subtotal	**3,668,211**	3,769,625
Total	**4,164,104**	4,212,730

16. Capital commitments

	Group	
	As at 30 June 2026 RMB'000	As at 31 December 2025 RMB'000
Contractual obligations to purchase and construct	**17,822**	17,938

17. Categories of financial assets and liabilities

	Group	
	As at 30 June 2026 RMB'000	As at 31 December 2025 RMB'000
Financial assets		
Financial assets at amortised cost	**6,217,253**	7,363,268
Financial liabilities		
Financial liabilities at amortised cost	**4,175,996**	4,222,912

18. Whether the same accounting policies and methods of computation as in the issuer's most recently audited annual financial statements have been applied

The Group has applied the same accounting policies and method of computation as presented in the audited financial statements of the Group for the reporting year ended 31 December 2025.

19. Earnings per ordinary share of the group for the current financial period reported on and the corresponding period of the immediately preceding financial year, after deducting any provision for preference dividends:
(a) Based on the weighted average number of ordinary shares on issue; and
(b) On a fully diluted basis (detailing any adjustments made to the earnings)

	Group	
	6-month period ended 30 June 2026	6-month period ended 30 June 2025
	RMB	RMB
Based on weighted average number of ordinary shares in issue	**0.84**	2.50

Diluted earnings per share is the same as basic earnings per share as the Company does not have any potential ordinary shares that have a dilutive effect on earnings per share as at the end of the period reported on.

20. Net asset value (for the issuer and group) per ordinary share based on the total number of issued shares excluding treasury shares of the issuer at the end of the:
(a) current financial period reported on; and
(b) immediately preceding financial year.

	Group		Company	
	As at 30 June 2026	As at 31 December 2025	**As at 30 June 2026**	As at 31 December 2025
	RMB	RMB	**RMB**	RMB
Net asset value per ordinary share based on existing issued share capital as at the end of the period reported on	**7.71**	9.22	**7.79**	9.34

21. A review of the performance of the group, to the extent necessary for a reasonable understanding of the group's business.

The financial performance is not significantly affected by any of the seasonality or cyclicality of interim operations.

(a) Revenue:

The Group's revenue in the second quarter of the financial year ending 31 December 2026 ("**2Q FY2026**") was approximately RMB 939 million, a decrease of approximately RMB 256 million, or 21%, from RMB 1,195 million in the second quarter of FY2025 ("**2Q FY2025**"). For the 6 months ended 30 June 2026 ("**1H26**"), the Group recorded a revenue of approximately RMB 2,455 million, a decrease of approximately RMB 196 million, or 7%, over the 6 months ended 30 June 2025 ("**1H25**"). This was mainly due to the combined effect of changes in the industry environment and slower market demand, which reduced revenue year on year.

(b) Gross Profit Margin:

The Group's gross profit in 2Q FY2026 was approximately RMB 672 million, a decrease of approximately RMB 211 million compared to 2Q FY2025. For 1H26, the Group's gross profit was approximately RMB 1,827 million, a decrease of approximately RMB 109 million compared to 1H25. The gross profit margin increased slightly from 73% in 1H25 to 74% in 1H26, remaining broadly stable..

(c) Other Gains:

Other gains in 2Q FY2026 were approximately RMB 15 million. For 1H26, the Group's other gains were approximately RMB 35 million, a decrease of approximately RMB 1,568 million over the previous corresponding period. The decrease was mainly attributable to the recognition of two gains in 1H25, namely (i) a gain of approximately RMB1,543 million arising from the disposal of the remaining 12% equity interest in Sino-American Tianjin SmithKline & French Lab., Ltd. (中美天津史克制药有限公司) ("**Sino-American Tianjin**"), a former associated company of the Company, and (ii) a gain of approximately RMB17 million arising from the deconsolidation of Tianjin Shin Poong Pharmaceutical Co., Ltd. (天津新丰制药有限公司), a former subsidiary of the Company, after the court ruled to accept the application for its bankruptcy liquidation and appointed a bankruptcy administrator, partially offset by a gain of approximately RMB 2 million arising from the liquidation of Bio-Chip Co., a former associated company of the Company, in 1H26.

(d) Major Expenses:

(i) Marketing and Distribution costs in 2Q FY2026 were approximately RMB 265 million, a decrease of approximately RMB 211 million compared to 2Q FY2025. For 1H26, the Marketing and Distribution costs were approximately RMB 799 million, a decrease of approximately RMB

222 million, or 22%, over the previous corresponding period. This was mainly due to lower revenue, changes in product mix, and the further deepening of marketing reforms, including the optimisation of selling expenses through more targeted marketing strategies.

(ii) Research and Development ("**R&D**") costs in 2Q FY2026 were approximately RMB 50 million, an increase of approximately RMB 14 million, or 40%, over the previous corresponding period. For 1H26, the R&D costs increased by approximately RMB 18 million, from approximately RMB 62 million in 1H25 to approximately RMB 80 million. This was mainly due to an increase in R&D investment compared to the same period in FY2025.

(iii) Administrative expenses in 2Q FY2026 increased by approximately RMB 8 million, from approximately RMB 101 million in 2Q FY2025. For 1H26, the administration expenses were approximately RMB 204 million, an increase of approximately RMB 13 million as compared to 1H25. This was primarily due to the year-on-year increase in brand promotion expenditure.

(iv) Finance costs in 2Q FY2026 decreased by approximately RMB 0.04 million to approximately RMB 0.13 million. For 1H26, the finance costs were approximately RMB 0.31 million, a decrease of approximately RMB 0.11 million over the previous corresponding period.

(v) Other losses in 2Q FY2026 increased by approximately RMB 8 million. For 1H26, the other losses were approximately RMB 51 million, an increase of approximately RMB 30 million over the previous corresponding period. This was mainly due to a year-on-year increase in provision for inventory obsolescence.

(e) Share of results of associated companies:

The Group's share of profits of associated companies in 2Q FY2026 was approximately RMB 5 million. The Group's share of profits of associated companies in 1H26 increased from approximately RMB 17 million to approximately RMB 18 million.

(f) Total comprehensive income:

The Group's total comprehensive income (net of tax) in 2Q FY2026 was approximately RMB 220 million, a decrease of 86% over the previous corresponding period. The Group's total comprehensive income (net of tax) in 1H26 was approximately RMB 642 million, a decrease of approximately RMB 1,280 million, or 67%, over the previous corresponding period.

The profit attributable to equity holders of parent (net of tax) in 2Q FY2026 was approximately RMB 220 million, a decrease of 86% over the previous corresponding period. The profit attributable to equity holders of parent (net of tax) in 1H26 was approximately RMB 643 million, a decrease of approximately RMB 1,284 million, or 67%, from approximately RMB 1,927 million in 1H25. This was mainly due to the disposal of the remaining 12% equity interest in Sino-American Tianjin in the corresponding period, which generated a net after-tax gain of approximately RMB1,308 million.

(g) Major changes in statement of financial positions:

(i) As at 30 June 2026, the Group's cash and cash equivalents amounted to approximately RMB 2,448 million, which was an increase of approximately RMB 1,431 million, or 141%, over the balance as at 31 December 2025. This was mainly due to the maturity and redemption of deposit products, such as large-denomination certificates of deposit, in preparation for the payment of dividend.

(ii) Trade and other receivables decreased by approximately RMB 112 million, or 7%, from approximately RMB 1,604 million at the beginning of the year to approximately RMB 1,492 million as at 30 June 2026.

(iii) Inventories were approximately RMB 1,111 million at 30 June 2026, which was a decrease of approximately RMB 22 million, or 2%, over the balance as at 31 December 2025.

(iv) Other current assets amounted to approximately RMB 93 million as at 30 June 2026, representing an increase of approximately RMB 7 million, or 9%, from approximately RMB 85 million as at the beginning of the year.

(v) Investment in associates of the Group increased by 1% to approximately RMB 1,177 million.

(vi) Property, plant and equipment decreased by approximately RMB 25 million to approximately RMB 1,109 million.

(vii) Other financial assets decreased by approximately RMB 2,466 million, or 52%, to approximately RMB 2,277 million. This was mainly because certain large-denomination certificates of deposit matured during the current financial period reported on, with the proceeds applied towards the payment of dividend.

(h) Change in cash flow position:

(i) In 1H26, the Group recorded net cash inflow from operating activities of approximately RMB 827 million, which increased by approximately RMB 600 million as compared to 1H25. This was mainly due to a yere-on-year increase in cash received from the discounting of bank acceptance bills during the current financial period reported on, as the Group took advantage of the low discount rates in the financial market to earn interest spread income.

(ii) Cash inflow from investing activities was approximately RMB 2,485 million in 1H26, an increase of approximately RMB 2,028 million as compared to 1H25. This was mainly attributable to the maturity and recovery of existing deposit products, such as large-denomination certificates of deposit, during the current financial period reported on.

(iii) Cash outflow from financing activities was approximately RMB 1,880 million in 1H26, an increase of approximately RMB 1,879 million as compared to 1H25. This was mainly due to the payment of the interim dividend in respect of FY2025 during the current financial period reported on, whereas no corresponding interim dividend was paid in 1H25.

22. Forecast, or a prospect statement

There was no forecast or a prospect statement that had been previously disclosed to shareholders.

23. Significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months

2026 marks the first year of the 15th Five-Year Plan period. The National Administration of Traditional Chinese Medicine ("**TCM**") and other government departments jointly issued the Plan for the Revitalisation and Development of Traditional Chinese Medicine during the 15th Five-Year Plan Period (《中医药振兴发展"十五五"规划》) (the "**Plan**"), which sets the overall goal of achieving "TCM services for all" by 2030 and sets out ten key tasks, including improving the high-quality service system, promoting the integration of Chinese and Western medicine, and accelerating digital and intelligent enablement.

Against this backdrop, the industry is presented with a number of opportunities. On the policy front, both the number and proportion of Chinese patent medicines in the new National Essential Medicines List have increased, and Category 1 innovative TCM drugs have been included for the first time. The "three-combination" review system has been incorporated into the relevant regulations, providing an institutional pathway for the commercialisation of classical formulae and creating a window for the re-rating of time-honoured brands with exclusive products. At the primary care level, the Action Plan for Traditional Chinese Medicine under the Healthcare Capacity Building Programme (《医疗卫生强基工程中医药行动方案》) calls for the development of county-level TCM specialty departments, and the proportion of township health centres able to provide appropriate TCM therapies is expected to increase gradually, supporting continued expansion of the primary care market. In terms of new business models, the Plan encourages the growth of TCM health services, and an ageing population is driving strong demand in emerging areas such as integrated medical and elderly care and products based on medicinal food homology.

At the same time, the industry faces structural challenges. In relation to centralised volume-based procurement, the fourth national round for Chinese patent medicines has, for the first time, included over-the-counter products on a large scale, continuing to compress industry profit margins. On costs, the prices of certain Chinese medicinal materials have fluctuated significantly, while standardised cultivation has yet to achieve full coverage, placing pressure on cost control. On compliance, a large number of product approvals face re-registration pressure under the new safety requirements for package inserts, accelerating the elimination of less competitive market participants. In addition, differences in overseas registration standards have long constrained exports of Chinese patent medicines and slowed the pace of internationalisation, while a shortage of multi-skilled talent continues to limit the ability to translate innovation into commercially viable products. Taken together, these pressures are driving the industry into a phase of deeper consolidation and quality-driven upgrading.

In response to these opportunities and challenges, the Company has anchored its efforts around the "1+5" priorities, with a brand-led strategy at its core and a focus on research and innovation, marketing reform, operational excellence, organisational revitalisation and strategic coordination. The Group will further implement the Suxiao Jiuxin public welfare campaign 3.0, build AI-based consumer awareness infrastructure and strengthen its terminal channels. Drawing on its 122 exclusive products and two state-classified confidential formulations, it will progressively pursue the secondary development of existing products, the development and commercialisation of classical formulae and the cultivation of health and wellness products. Growth will be driven by marketing reform, with coordinated efforts across product optimisation, deeper regional penetration, primary care expansion and overseas development. Operational excellence will be pursued on multiple fronts, with a focus on quality control, cost reduction and efficiency improvement. Organisational revitalisation will be deepened through regional marketing reform and digital and AI-enabled business upgrading, and strategic coordination will be strengthened through closer industry-commerce collaboration and employee care initiatives.

Looking ahead to the 15th Five-Year Plan period, the Group will continue to optimise its product portfolio, increase investment in research and development, advance the construction of standardised medicinal material bases, and accelerate the recruitment and development of multi-skilled talent, while advancing brand upgrading and global expansion. Through these efforts, the Group aims to progress towards its strategic goal of becoming a leader in modern Chinese medicine and contribute to the Healthy China initiative.

24. If a decision regarding dividend has been made:
(a) Whether an interim (final) ordinary dividend has been declared (recommended)
(b) The amount per share, as well as for the previous corresponding period
(c) Whether the dividend is before tax, net of tax or tax exempt. If before tax or net of tax, state the tax rate and the country where the dividend is derived. (If the dividend is not taxable in the hands of shareholders, this must be stated)
(d) The date the dividend is payable
(e) The date on which Registrable Transfers received by the company (up to 5.00 pm) will be registered before entitlements to the dividend are determined

If no dividend has been declared (recommended), a statement to that effect and the reason(s) for the decision.

No dividend has been declared for the current financial period reported on. The Company will conduct a review at the end of the financial year.

Please refer to Note 5 above for details of the dividends in respect of FY2025 that were paid during the current financial period reported on.

25. Related party transactions

There are transactions and arrangements between the Group and its subsidiaries and associates, and the effects of these transactions as determined between the parties are reflected in these condensed consolidated interim financial statements. The related company balances and transfer of resources, services or obligations (if any) are unsecured, without fixed repayment terms and interest or charge unless stated otherwise.

Intra-group transactions and balances that have been eliminated in these condensed consolidated interim financial statements are not disclosed as related party transactions and balances below.

In addition to the transactions and balances disclosed elsewhere in the notes to the financial statements, this item includes the following:

	6-month period ended 30 June	
	2026 **RMB'000**	2025 RMB'000
Sale of goods to associates	**177,849**	35,436
Purchase of goods from associates	**(14,578)**	(11,027)
Interest income from an associate	**9,692**	3,989
Interest expense payable to an associate	**-**	-
Rental income from an associate	**2,261**	-

	6-month period ended 30 June	
	2026 **RMB'000**	2025 RMB'000
Sale of goods to related companies	**103,425**	259,751
Purchase of goods from related companies	**(6,410)**	(5,669)
Rental expenses to related companies	**(1,394)**	(1,538)
Rental income from related companies	**-**	108
Purchase of assets from related companies	**-**	-

26. Interested Person Transaction disclosure

The Group has obtained a general mandate (the "**IPT General Mandate**") from the Shareholders for interested person transactions (the "**IPTs**", and each, an "**IPT**") at the annual general meeting held on 15 May 2026 for FY2025. Please refer to the annexure dated 30 April 2026 accompanying the notice of annual general meeting in relation to the proposed renewal of the IPT General Mandate (as set out on pages 176 to 201 of the Company's annual report for FY2025) for further details. During the current financial period reported on, there are no IPTs (excluding transactions less than S$100,000) entered into with the mandated interested persons that are conducted under the IPT General Mandate.

Shareholders' approval was also obtained for the Company's entry into a financial services agreement with Tianjin Pharmaceutical Group Finance Co., Ltd. (天津医药集团财务有限公司) ("**TPGF**") as an IPT and all transactions arising therefrom at the annual general meeting held on 15 May 2026 for FY2025. Please refer to the annexure dated 30 April 2026 (the "**30 April 2026 Annexure**") accompanying the notice of annual general meeting in relation to the foregoing IPT for further details. For the avoidance of doubt, the Company has sought and obtained Shareholders' approval for its entry into the aforesaid financial services agreement as a specific IPT. Therefore, the value of transactions conducted thereunder is not disclosed as transactions covered under the IPT General Mandate pursuant to Rule 920 of the Listing Manual.

Accordingly, the aggregate value of all IPTs during the current financial period reported on (excluding transactions less than S$100,000) is as follows:

Name of Interested Person	Nature of relationship	Aggregate value of all interested person transactions during the financial period under review (excluding transactions less than S$100,000 and transactions conducted under shareholders' mandate pursuant to Rule 920 of the Listing Manual)		Aggregate value of all interested person transactions conducted during the financial period under review under a shareholders' mandate pursuant to Rule 920 of the Listing Manual (excluding transactions less than S$100,000)	
		6-month period ended 30 June 2026	6-month period ended 30 June 2025	**6-month period ended 30 June 2026**	6-month period ended 30 June 2025

		RMB'000	RMB'000	RMB'000	RMB'000
Tianjin Pharmaceutical Group Finance Co., Ltd (天津医药集团财务有限公司) (i.e. TPGF)	Subsidiary of Tianjin Pharmaceutical Holdings Co., Ltd. (天津市医药集团有限公司) ("**TPH**"), the controlling shareholder of the Company	The interest payable on the credit facilities provided by TPGF: **-**	-	-	-
Tianjin Zhongxin Medicine Co., Ltd. (天津中新医药有限公司) ("**TJZX Medicine**")	Subsidiary of Tianjin Pharmaceutical Group Taiping Medicine Co., Ltd. (津药太平医药有限公司) ("**Taiping Medicine**"), in which the Company and TPH hold 43.35% and 56.65%, respectively	Provision of guarantee by the Company for TJZX Medicine: **240,063**	248,612	-	-
Taiping Medicine	Subsidiary of TPH	Provision of guarantee by the Company for Taiping Medicine: **104,455**	-	-	-
Taiping Medicine	Subsidiary of TPH	Rent payable by Taiping Medicine: **14,786**	14,786	-	-
Total		359,304	263,398	-	-

Note(s):

(1) As at 30 June 2026, the placement of deposit with TPGF amounted to approximately RMB 1,358.97 million.

(2) For the avoidance of doubt, the rent payable by Taiping Medicine disclosed above represents the total rent payable over the full term of the lease agreement entered into between the Company and Taiping Medicine, with a lease term from 1 July 2025 to 30 June 2028, and does not represent a new or additional transaction entered into during the current financial period reported on. This amount was originally disclosed by the Company

in its 2Q FY2025 results announcement and has continued to be reflected in the Company's subsequent periodic disclosures. It is repeated here for continuity of disclosure and information purposes only.

As disclosed in the 30 April 2026 Annexure, TPGF shall provide certain financial services to the Company under the aforesaid financial services agreement, including deposit services.

As further disclosed in the 30 April 2026 Annexure, the deposit services provided by TPGF will enhance the Company's fund management and utilisation of available funds, as:

(i) TPGF provides secure and efficient online banking services, enabling the Company to monitor its account balances and fund movements in a timely manner;

(ii) payments and settlements may be conducted efficiently through TPGF's internal transfer mechanisms, facilitating convenient fund transfers between the Company and its branches; and

(iii) TPGF is able to provide timely credit support to the Company, thereby reducing the need for the Company to maintain excessive cash reserves.

In this regard, as disclosed in the 30 April 2026 Annexure, the Company shall open a deposit account with TPGF and, and, on a free deposit and withdrawal basis, place its funds into the deposit account maintained with TPGF. Further, the maximum daily balance in the deposit account (including accrued interest) shall not exceed RMB 1,500 million. Please refer to the 30 April 2026 Annexure for further details on the scope and terms of the financial services provided by TPGF to the Company under the aforesaid financial services agreement.

Shareholders' approval for the Company's entry into the aforesaid financial services agreement was obtained at the annual general meeting of the Company held on 15 May 2026 for FY2025.

The deposit of approximately RMB 1,358.97 million placed with TPGF as at 30 June 2026 falls within the limit of RMB 1,500 million. Further details on the deposit are set out below:

Unit: RMB '000

Duration of deposit	**Current deposit (1-7 days)**	**Fixed deposit (12 months)**	**Fixed deposit (12 months - 36 months)**	**Total**
Balance of deposit	1,068,965.80	90,000.00	200,000.00	1,358,965.80

Note: The Company may withdraw the "current deposit" at any time and may only withdraw the "fixed deposit" after its maturity.

Pursuant to Rule 904 of the Listing Manual, an "interested person transaction" means a transaction between an entity at risk and an interested person, and "transaction" includes, amongst others, the provision or receipt of goods or services, whether or not in the ordinary course of business, and whether or not entered into directly or indirectly (for example, through one or more interposed entities). As TPGF is a subsidiary of TPH, the controlling shareholder of the Company, the deposit services provided by TPGF to the Company constitute an IPT. However, the deposit of approximately RMB 1,358.97 million placed with TPGF as at 30 June 2026 has not been included in the IPT table set out above to prevent confusion to Shareholders. Due to the nature of deposit, the monies deposited in the account can be withdrawn and/or deposited as and when necessary, save as disclosed above in relation to fixed deposit and subject to the maximum daily balance limit as stated above. As such, it is not calculated across a financial period, and the Company is of the view that it is more meaningful to disclose the amount of the deposit placed with TPGF as at the end of the financial period under review. Accordingly, this disclosure has been presented separately from the IPT table set out above.

27. Confirmation that the issuer has procured undertakings from all its directors and executive officers (in the format set out in Appendix 7.7) under Rule 720(1) of the Listing Manual

The Company confirms that it has procured undertakings from all its directors and executive officers (in the format set out in Appendix 7.7) under Rule 720(1) of the Listing Manual.

28. Person occupying a managerial position in the issuer or any of its principal subsidiaries who is a relative of a director or chief executive officer or substantial shareholder of the issuer pursuant to Rule 704(13) of the Listing Manual

Pursuant to Rule 704(13) of the Listing Manual, the Company confirms that, to the best of its knowledge, belief and information, as of the date hereof, none of the persons occupying managerial positions in the Company or any of its principal subsidiaries is a relative of a Director, Chief Executive Officer or Substantial Shareholder of the Company.

29. Statement pursuant to Rule 705(5) of the Listing Manual

The Board of Directors confirm that, to the best of their knowledge, nothing has come to the attention of the Board of Directors which may render the unaudited interim consolidated financial results for the financial period ended 30 June 2026, to be false or misleading in any material respect.

30. Additional information required on acquisitions and realisations pursuant to Rule 706A of the Listing Manual

As disclosed in Note 4 above, for the current financial period reported on, the Group had not disposed of shares resulting in a company ceasing to be a subsidiary or an associated company of the Company, and had also not disposed of shares resulting in the Company reducing its shareholding percentage in a subsidiary or an associated company.

As disclosed in Note 6 above, for the current financial period reported on, the Group had not acquired any shares of a company resulting in such company becoming a subsidiary or an associated company of the Company, and had also not acquired any shares resulting in the Company increasing its shareholding percentage in a subsidiary or an associated company.